Bibliographic Details
| Title: |
Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study |
| Authors: |
Wei Fang, Xingqiao Peng, Qun Zhou |
| Source: |
Journal of Cardiothoracic Surgery, Vol 19, Iss 1, Pp 1-8 (2024) |
| Publisher Information: |
BMC, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Surgery
LCC:Anesthesiology |
| Subject Terms: |
NSCLC, Pemetrexed, Bevacizumab, Overall survival, Progression-free survival, Surgery, RD1-811, Anesthesiology, RD78.3-87.3 |
| More Details: |
Abstract Background Combining pemetrexed with bevacizumab may have some potential in improving the efficacy in patients with non-small-cell lung cancer (NSCLC), and this meta-analysis aims to explore the impact of pemetrexed addition to bevacizumab on treatment efficacy for NSCLC. Methods PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched, and we included randomized controlled trials (RCTs) assessing the effect of pemetrexed addition to bevacizumab on treatment efficacy in patients with NSCLC. Overall survival and progression-free survival were included in this meta-analysis. Results Four RCTs were finally included in the meta-analysis. Overall, compared with bevacizumab for NSCLC, pemetrexed addition showed significantly improved overall survival (hazard ratio [HR] = 0.87; 95% confidence interval [CI] = 0.76 to 0.99; P = 0.03), survival rate (odd ratio [OR] = 1.41; 95% CI = 1.06 to 1.86; P = 0.02), progression-free survival (HR = 0.63; 95% CI = 0.55 to 0.72; P |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1749-8090 |
| Relation: |
https://doaj.org/toc/1749-8090 |
| DOI: |
10.1186/s13019-024-02975-6 |
| Access URL: |
https://doaj.org/article/302cacf41a744f538af40572edefc028 |
| Accession Number: |
edsdoj.302cacf41a744f538af40572edefc028 |
| Database: |
Directory of Open Access Journals |
